Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Some extracts from the Cohen Report

years (I'm assuming that's Crossflo) with another 100 million from the MMP.

The MMP projection IMO is just a very simplified project in to the future based on the revenue received over the past 3 years.

From P. 17:

The growth story is exciting. We forecast non-IP licensing revenues in 2009 of $8.6 million will grow

to $64.5 million in FY13. Our forecast assumes flat IP licensing revenues, which is reported as Equity

in Earnings of Affiliates. Operating margin is forecasted to be positive in FY10 and expand through

FY13. Free cash flow is positive throughout our forecast and the Company is expected to maintain a

strong liquidity position. We do not incorporate any additional acquisitions into our forecast. EPS is

expected to grow at a compound annual rate of 35% from FY08 through FY13.





Share
New Message
Please login to post a reply